Poor Prognosis of Pulmonary Adenosquamous Carcinoma with NRAS and HRAS Double Mutation
Open Access
- 1 February 2021
- journal article
- research article
- Published by Taylor & Francis Ltd in OncoTargets and Therapy
- Vol. ume 14, 1113-1116
- https://doi.org/10.2147/ott.s295813
Abstract
RAS mutations constitute one of the major tumorigenic mechanisms and are detected in approximately 20% of lung cancers. The most frequent mutated and well-studied RAS isoform is KRAS, which is associated with an overall poor prognosis in non-small-cell lung cancer (NSCLC). However, the clinical significances of NRAS and HRAS in NSCLC are rarely reported. Here, we present a 58-year-old male smoker who was diagnosed with stage IV lung adenosquamous carcinoma. A rare NRAS and HRAS double mutation was detected in the primary tumor and lymph node samples using next-generation sequencing (NGS). The patient showed rapid disease progression and passed away due to respiratory failure after 15 days of osimertinib in combination with cisplatin. To the best of our knowledge, this is the first report associating NRAS and HRAS double mutation in the poor prognosis of NSCLC.Keywords
This publication has 12 references indexed in Scilit:
- Mutational analysis ofRashotspots in patients with urothelial carcinoma of the bladderWorld Journal of Clinical Oncology, 2020
- The mutational landscape of mucosal melanomaSeminars in Cancer Biology, 2019
- Diagnostic Value of RAS Mutations in Indeterminate Thyroid Nodules: Systematic Review and Meta‐analysisOtolaryngology -- Head and Neck Surgery, 2017
- KRAS, NRAS and BRAF mutations in colorectal cancer and melanomaMedical Oncology, 2017
- Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokersLung Cancer, 2016
- HRAS G13D, a new mutation implicated in the resistance to anti-EGFR therapies in colorectal cancer, a case reportInternational Journal of Colorectal Disease, 2015
- Drugging the undruggable RAS: Mission Possible?Nature Reviews Drug Discovery, 2014
- Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2014
- KRAS Mutations in Lung CancerClinical Lung Cancer, 2013
- Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesisJCI Insight, 2007